Liraglutide accelerates colonic transit in people with type 1 diabetes and polyneuropathy: A randomised, double-blind, placebo-controlled trial.

Anne-Marie Langmach WegebergChristian Stevns HansenAdam D FarmerJesper Scott KarmisholtAsbjorn M DrewesPoul Erik JakobsenBirgitte BrockChristina Brock

Published in: United European gastroenterology journal (2020)

Liraglutide accelerates large bowel transit and decreases motility index, which may indicate better coordination of propulsive motility. This potentially improves the function of the enteric nervous system, leading to normalised colonic function and positive effects in type 1 diabetes.

Keyphrases

double blind
type diabetes
placebo controlled
clinical trial
study protocol
biofilm formation
ulcerative colitis
open label
cardiovascular disease
phase iii
phase ii
glycemic control
pseudomonas aeruginosa
candida albicans